Daily FNArena News - Small Caps

The New Criterion’s Tim Boreham explains the how and why behind Radiopharm Theranostics’ latest capital raising

Brokers highlight deregulation and scale benefits from the potential merger of Integral Diagnostics and Capitol Health 

Deterra Royalties is looking to diversify away from iron ore royalties and provide for growth, in lithium in particular. The trade-off is a much-reduced dividend yield

Codan has surprised with the performance of its metal detection business, but it is the company’s communications business that has brokers excited

The next twelve months could be exciting for Dengue fever solutions seeker Island Therapeutics, the New Criterion’s Tim Boreham reports

Alternative asset manager Regal Partners has enjoyed impressive organic and inorganic funds under management growth in recent years and brokers see more ahead

With the costly decommissioning of the BMG field now behind it, Cooper Energy has outlined its strategy to exploit a tight east coast gas market

A lack of junior miner exploration in tough economic times has weighed on drill supplier Imdex, but brokers believe an upswing is not too far off

Amplia Therapeutics is in pursuit of a cancer drug for pancreatic cancer and possibly other indications including ovarian cancer, the New Criterion’s Tim Boreham reports

With the Big Four banks regarded as overvalued, investors are pondering whether there’s better value in their smaller counterparts that trade on more modest valuations but with similar or higher dividend yields